40. Implantables: progestin Trade name Unit Duration of action: Levonorgestrel Norplant 6 capsules 5 years. Etonegestrel Implanon 1 rod 3 years. Nestrone Elcometrine 1 capsule 6 months. Nestrone Elcometrine 1 rod 2 years. Norgestrol Unilant/ Surplant 1 rod 1 year Levonorgestrel Jedelle/Norplant II 2 rods 5 years
77. WHO Guidance Allows More Women to Use IUDs World Health Organization, 2004 PID Purulent cervicitis, chlamydia, or gonorrhea Other STIs HIV AIDS Clinically well on ART Not well on or not taking ART Condition Exists Before Insertion Do not insert (Category 4) Do not insert (Category 4) Generally can insert (Category 2) Generally can insert (Category 2) Generally can insert (Category 2) Usually do not insert (Category 3) Condition Develops After Insertion Generally can keep her IUD while being treated (Category 2) Generally can keep her IUD while being treated (Category 2) Generally can keep her IUD while being treated (Category 2) Generally can keep her IUD (Category 2) Generally can keep her IUD (Category 2) At High Individual Risk for Condition NA Usually do not insert (Category 3) NA Generally can insert (Category 2) NA NA
Duration of use: TCu-380A: up to 10 years, and may be extended to 12 years Multiload-375: up to 5 years Levonorgestrel-releasing IUD (LNG-IUD): up to 5 years, and maybe longer The U.S. Agency for International Development (USAID) supplies the TCu-380A to developing-country programs. The two other major donors of contraceptives, the United Nations Population Fund (UNFPA) and the International Planned Parenthood Federation (IPPF), provide both the TCu-380A and the Multiload-375. The LNG-IUD, marketed under the brand names Mirena ® and, in some European countries, Levonova ® , has been sold in Europe since 1990. Its high cost and the need to train providers in a new insertion technique have discouraged USAID from distributing it.
Sources: TCu-380A effectiveness: United Nations Development Program, 1997 LNG-IUD effectiveness: Luukkainen, 1987; Sivin, 1984 TCu-380A vs. LNG-IUD comparative study: World Health Organization, 2003
Changes to the WHO guidance now allow women with STIs other than gonorrhea, chlamydia, or purulent cervicitis to have IUDs inserted. Purulent cervicitis is an infection of the cervix with a pus-like discharge from the opening of the cervix. It may be a sign of a gonorrhea or chlamydial infection. There is concern that a woman at very high individual risk of gonorrhea or chlamydia may currently have gonorrhea or chlamydia but without any immediate symptoms. Only laboratory testing would detect these silent infections, and in many places these tests are not available. If a woman lives in a setting with a high prevalence of STIs but she herself is not at increased risk of STIs, then she generally can have an IUD inserted (category 2). WHO Medical Eligibility Criteria Classification: Category 1: Use the method in any circumstances. Category 2: Generally use the method. Category 3: Use of the method not usually recommended unless other more appropriate methods are not available or not acceptable. Category 4: Method not to be used. When clinical judgment is limited, interpretation of Categories 1 and 2: Yes (Use the method.) (shown in green in the chart on this slide) Categories 3 and 4: No (Do not use the method.) (shown in red in the chart on this slide)